Granted Patent
B2
US 12,703,856 · App. 18/630,991 · Granted Aug 11, 2026
Methods for reducing elevated glucose levels
Assignee:
SDF BioPharma, Inc
C12N5/0676A61K35/17A61K35/39A61P3/10C07K14/522C12N5/0635C12N5/0638C12N5/0646C12N5/0686C12N2501/998C12N2502/11C12N2502/99C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
Claims (18)
1 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a population of human beta cells that expresses or overexpresses a human fugetactic agent in an amount sufficient to render said beta cell resistant to human immune cells, wherein said beta cell is capable of expressing insulin.
2 . The pharmaceutical composition according to claim 1 , wherein said human beta cell comprises a vector that itself comprises a nucleic acid sequence encoding human CXCL12 wherein said beta cell is resistant to human immune cells.
3 . The pharmaceutical composition according to claim 1 , wherein said human beta cell is an autologous beta cell obtained from a subject with type 1 diabetes.
4 . The pharmaceutical composition according to claim 1 , wherein said human beta cell is an allogenic beta cell.
5 . The pharmaceutical composition according to claim 1 , wherein said human immune cells comprise NK cells, cytotoxic T cells and/or B cells.
6 . The pharmaceutical composition according to claim 1 , wherein said human beta cell expresses human CXCL12 at a fugetactic amount.
7 . The pharmaceutical composition according to claim 1 , wherein said CXCL12 is selected from the group consisting of CXCL12 alpha and CXCL12 beta.
8 . The pharmaceutical composition according to claim 1 , wherein said human beta cell comprises a transgenic regulatory region upstream of an endogenous CXCL12 coding region wherein said beta cell is resistant to human immune cells.
9 . The pharmaceutical composition according to claim 8 , wherein said human beta cell is an autologous beta cell.
10 . The pharmaceutical composition according to claim 8 , wherein said human beta cell is an allogenic beta cell.
11 . The pharmaceutical composition according to claim 8 , wherein said human beta cell is an autologous beta cell obtained or derived from a subject with type 1 diabetes.
12 . The pharmaceutical composition according to claim 9 , wherein said human beta cell is an allogeneic beta cell obtained or derived from a subject free of type 1 diabetes.
13 . The pharmaceutical composition according to claim 8 , wherein the transgenic regulatory region is an exogenous constitutive, or inducible promoter.
14 . The pharmaceutical composition according to claim 8 , wherein said human beta cell expresses human CXCL12 beta.
15 . The pharmaceutical composition according to claim 1 , wherein said human beta cell is incapable of cell division.
16 . The pharmaceutical composition according to claim 1 , wherein the human CXCL12 is selected from the group consisting of CXCL12 alpha, CXCL12 beta, CXCL12 delta, and CXCL12 gamma.
17 . The pharmaceutical composition according to claim 1 , wherein said human immune cells comprise NK cells, cytotoxic T cells and B cells.
18 . The pharmaceutical composition according to claim 1 , wherein said pharmaceutical excipient is a sterile aqueous solution.
Assignments (2)
CHANGE OF NAME
Recorded Nov 24, 2025
From: WALLKILL BIOPHARMA INC.
To: SDF BIOPHARMA INC.
Reel/Frame 073784/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 24, 2025
From: SWISS, GERALD F.; KIEWLICH, DAVID
To: WALLKILL BIOPHARMA, INC.
Reel/Frame 073023/0038 →
Continuity (11)
Provisional Application
62734910
· Sep 21, 2018
Provisional Application
62719975
· Aug 20, 2018
Provisional Application
62717587
· Aug 10, 2018
Provisional Application
62696603
· Jul 11, 2018
Provisional Application
62694634
· Jul 6, 2018
Provisional Application
62662651
· Apr 25, 2018
Provisional Application
62637913
· Mar 2, 2018
Provisional Application
62568117
· Oct 4, 2017
Provisional Application
62567604
· Oct 3, 2017
Related Publication
20240360418A1
· Oct 31, 2024
References Cited (123)
US 5756084A
· Honjo et al.
· 1998
[cited by applicant]
US 6448054B1
· Poznansky et al.
· 2002
[cited by applicant]
US 7033831B2
· Fisk et al.
· 2006
[cited by applicant]
US 7776564B2
· Chu et al.
· 2010
[cited by applicant]
US 8268620B2
· Thomson et al.
· 2012
[cited by applicant]
US 8546140B2
· Mack et al.
· 2013
[cited by applicant]
US 20080213319A1
· Kang et al.
· 2008
[cited by applicant]
US 20090280096A1
· Kubo et al.
· 2009
[cited by applicant]
US 20120053119A1
· Habener et al.
· 2012
[cited by applicant]
US 20170196913A1
· Ben-Porath et al.
· 2017
[cited by applicant]
US 20190100729A1
· Kiewlich et al.
· 2019
[cited by applicant]
WO 2012025925A1
· 2012
[cited by applicant]
Kiewlich Declaration signed Nov. 20, 2019, and submitted in U.S. Appl. No. 16/370,606.
[cited by applicant]
Altieri, P., et al., 5-fluorouacil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1, British Journal of Pharmacology, 2017, 171, pp. 3713-3726.
[cited by applicant]
Xiao, H., et al., Angelica sinensis Polysaccharides Ameliorate Stress-Induced Premature Senescence of Hematopoietic Cell via Protecting Bone Marrow Stromal Cells form Oxidative Injuries Caused by 5-Fluorouracil, Int. J.…
[cited by applicant]
Notice of Allowance dated Apr. 14, 2023, for U.S. Appl. No. 17/522,538, 7 pgs.
[cited by applicant]
Non Final Office Action dated Feb. 17, 2023, for U.S. Appl. No. 17/522,538.
[cited by applicant]
Burgess, W.H., et al., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a …
[cited by applicant]
Skolnick, J., et al., From Genes to Protein Structure and Function: Novel Applications of Computational Approaches n the Genomic Era, Trends in Biotech, vol. 18, Jan. 2000, pp. 34-39.
[cited by applicant]
Whisstock, J., et al., Prediction of Protein Function from Protein Sequence, Quarterly Reviews of Biophysics, Aug. 2003, 36(3), pp. 307-340.
[cited by applicant]
Wang, D., et al., A Single Amino Acid Determines Lysophospholipid Specificity of the S1P1 (EDG1) and LPA1 (EDG2) Phospholipid Growth Factor Receptors, The Journal of Biological Chemistry, 276(52), Dec. 28, 2001, pp. 492…
[cited by applicant]
Attwood, T.K, et al., The Babel of Bioinformatics, Science, 290(5491), Oct. 20, 2000, pp. 471-473.
[cited by applicant]
Transplantation, 2007, vol. 83, No. 2, pp. 174-183.
[cited by applicant]
PLOS ONE, 2013, vol. 8, Issue 3, e59679.
[cited by applicant]
Notice of Reasons for Rejection in related Japanese Application No. 2020-519249, paged 1-13.
[cited by applicant]
Yu, L., et al., Identification and expression of novel isoforms of human stromal cell-derived factor 1, Gene, 2006, 374, pp. 174-179.
[cited by applicant]
Sneddon, J., et al., Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges, Cell Stem Cell, 2018, 22, pp. 810-818.
[cited by applicant]
Ricordi, C., Lilly Lecture 2002—Islet Transplantation: A Brave New World, Diabetes, 2003, 52, pp. 1595-1603.
[cited by applicant]
King, A., The use of animal models in diabetes research, British Journal of Pharmacology, 2012, 166, pp. 877-894.
[cited by applicant]
Perlman, R, Mouse models of human disease: An evolutionary perspective, Evol. Med. Public Health, 2016, 2016 (1), pp. 170-176.
[cited by applicant]
Researchers find striking differences between human and animal insulin-producing islet cells, Diabetes Research Institute Foundation Press Release, Feb. 2006, [online] https://www.diabetesresearch.org/differences-betwee…
[cited by applicant]
Chong, A., et al., Lessons and Limits of Mouse Models, Cold Spring Harb. Perspect. Med., 2013, 3(12), pp. 1-16.
[cited by applicant]
Aboumrad, E., et al., The CXCR4/CXCL 12 (SDF-1) signaling pathway protects non-obese diabetic mouse from autoimmune diabetes, Clinical and Experimental Immunology, 2007, 148(3), pp. 432-439.
[cited by applicant]
Pericin, M., et al., Allogeneic β-islet cells correct diabetes and resist immune rejection, PNAS, 2002, 99(12), pp. 8203-8206.
[cited by applicant]
International Search Report and Written Opinion, PCT App No. PCT/US2018/053599, mailed Nov. 28, 2018, 14 pgs.
[cited by applicant]
Vianello, F., et al., Fugetaxis: active movement of leukocytes away from a chemokinetic agent, J. Mol. Med., 2005, 83, 752-763.
[cited by applicant]
Poznansky, M., et al., Thymocyte emigration is mediated by active movement away from stroma-derived factors, J. Clin. Invest., 2002, 109(8), pp. 1101-1110.
[cited by applicant]
Sremac, M., et al., Preliminary Studies of the Impact of CXCL12 on the Foreign Body Reaction to Pancreatic Islets Microencapsulated in Alginate in Nonhuman Primates, Transplantation Direct, 2019, 5(5), e447.
[cited by applicant]
Massachusetts General Hospital, Protein that repels immune cells protects transplanted pancreatic islets from rejection: Transplanting islets encapsulated with CXCL 12 restores blood sugar control without immunosuppress…
[cited by applicant]
Cloning Technique Used to Create Pancreatic Cells for Type 1 Diabetes, Diabetes Community, Support, Education, Recipes & Resources, Apr. 29, 2019, 4 pgs., [online] https://www.diabetes.co.uknews/2014/apr/cloning-techniq…
[cited by applicant]
Baek., K., et al., Gene transfection for stem cell therapy, Current Stem Cell Reports, 2016, 2(1), pp. 52-61.
[cited by applicant]
Cabrera, O., et al., The unique cytoarchitecture of human pancreatic islets has implications for islet cell function, Proceedings of the National Academy of Sciences, 2006, 103(7), pp. 2234-2339.
[cited by applicant]
Cermak, T., et al., Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting, Nucleic Acids Research, 2011, 39(12), 11 pgs.
[cited by applicant]
Chira, S., et al., Progresses towards safe and efficient gene therapy vectors, Oncotarget, 2015, 6(31), pp. 30675-30703.
[cited by applicant]
Cong, L., et al., Multiplex genome engineering using CRISPR/Cas systems, Science, 2013, pp. 819-823.
[cited by applicant]
El-Haibi, C.P., et al., CXCL 13 mediates prostate cancer cell proliferation through JNK signaling and invasion through ERK activation, Cell Proliferation, 2011, 44(4), 16 pgs.
[cited by applicant]
Gonzalez, F., et al., An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells, Cell Stem Cell, 2014, 15(2), pp. 215-226.
[cited by applicant]
Hardee, C.L., et al., Advances in non-viral DNA vectors for gene therapy, Genes, 2017, 8(65), 22 pgs.
[cited by applicant]
He, X., et al., Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair, Nucleic Acids Research, 2016, 44(9), e85.
[cited by applicant]
Hockemeyer, D., et al., Genetic engineering of human pluripotent cells using TALE nucleases, Nature Biotechnology, 2011, 29(8), 731.
[cited by applicant]
Hsu, P.D., et al., Development and applications of CRISPR-Cas9 for genome engineering, Cell, 2014, 157(6), pp. 1262-1278.
[cited by applicant]
Johannesson, B., et al., Toward beta cell replacement for diabetes, The EMBO Journal, 2015, 34(7), pp. 841-855.
[cited by applicant]
Joung, J.K., et al., TALENs: a widely applicable technology for targeted genome editing, Nature Reviews Molecular Cell Biology, 2013, 14(1), pp. 49-55.
[cited by applicant]
Kelly, O.G., et al., Cell-surface markers for the isolation of pancreatic cell types derived from human embryonic stem cells, Nature Biotechnology, 2011, 29(8), 9 pgs.
[cited by applicant]
Kroon, E., et al., Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo, Nature Biotechnology, 2008, 26(4), pp. 443-452.
[cited by applicant]
Lowry, W.E., et al., Generation of human induced pluripotent stem cells from dermal fibroblast, Proceedings of the National Academy of Sciences, 2008, 105(8), pp. 2883-2888.
[cited by applicant]
Maherali, N., et al., Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution, Cell Stem Cell, 2007, 1(1), pp. 55-70.
[cited by applicant]
Mali, P., et al., RNA-guided human genome engineering via Cas9, Science 2013, 339(6121), pp. 823-826.
[cited by applicant]
Mestas, J., et al., Of mice and not me: differences between mouse and human immunology, The Journal of Immunology, 2004, 172(5), pp. 2731-2738.
[cited by applicant]
Miller, J.C., et al., A TALE nuclease architecture for efficient genome editing, Nature Biotechnology, 2010, 29(2), pp. 143-150.
[cited by applicant]
Millette, K., et al., Gene Editing and Human Pluripotent Stem Cells: Tools for Advancing Diabetes Diseases Modeling and Beta-Cell Development, Current Diabetes Reports, 2017, 17(11), 116.
[cited by applicant]
Millman, J.R., et al., Generation of stem cell-derived β-cells from patients with type 1 diabetes, Nature Communications, May 10, 2016, 7:11463, 9 pgs.
[cited by applicant]
Narayanavari, S.A., et al., Sleeping Beauty transposon vectors for therapeutic applications: advances and challenges, Cell and Gene Therapy Insights, 2017, 3(2), 28 pgs.
[cited by applicant]
Okita, K., et al., Generation of germline-competent induced pluripotent stem cells, Nature, 2007, 448(7151), pp. 313-318.
[cited by applicant]
Orlando, G., et al., Cell replacement strategies aimed at reconstitution of the B-cell compartment in type 1 diabetes, Diabetes, 2014, 63(5), pp. 1433-1444.
[cited by applicant]
Oumard, A., et al., Recommended method for chromosome exploitation: RMCE-based cassette-exchange systems in animal cell biotechnology, Cytotechnology 50.1-3, 2006, pp. 93-108.
[cited by applicant]
Pagliuca, F.W., et al., How to make a functional β-cell, Development, 2013, 140(12), pp. 2472-2483.
[cited by applicant]
Papeta, N., et al., Long-term survival of transplanted allogeneic cells engineered to express a T cell chemorepellent, Transplantation, 2007, 83(2), pp. 174-183.
[cited by applicant]
Park, I., et al., Reprogramming of human somatic cells to pluripotency with defined factors, Nature, 2008, 451, pp. 141-145.
[cited by applicant]
Perl, S., et al., Significant human β-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating, The Journal of Clinical Endocrinology & M…
[cited by applicant]
Petrova, N.V., et al., Small molecule compounds that induce cellular senescence, Aging Cell, 2016, 15(6), pp. 999-1017.
[cited by applicant]
Porteus, M.H., et al., Gene targeting using zinc finger nucleases, Nature Biotechnology, 2005, 23(8), pp. 967-973.
[cited by applicant]
Poznansky, M.C., et al., Active movement of T cells away from a Chemokine, Nature Medicine, 2000, 6(5), pp. 543-548.
[cited by applicant]
Qadir, M.M.F., et al., P2RY1/ALK3-expressing Cells with the Adult Human Exocrine Pancreas are BMP-7 Expandable and Exhibit Progenitor-like Characteristics, Cell Reports, 2018, 22(9), pp. 2408-2420.
[cited by applicant]
Qi, M., Transplantation of encapsulated pancreatic islets as a treatment for patients with type 1 diabetes mellitus, Advances in Medicine, 2014, vol. 2014, 15 pgs.
[cited by applicant]
Reyon, D., et al., FLASH, assembly of TALENs for high-throughput genome editing, Nature Biotechnology, 2012, 30(5), pp. 460-465.
[cited by applicant]
Russ, H.A., et al., Controlled induction of human pancreatic progenitors produces functional beta-like cells in vitro, The EMBO Journal, 2015, 34(13), pp. 1759-1772.
[cited by applicant]
Sakata, N., et al., Encapsulated islets transplantation: past, present, and future, World Journal of Gastrointestinal Pathophysiology, 2012, 3(1), pp. 19-26.
[cited by applicant]
Schuetz, C., et al., Islet cell transplantation: update on current clinical trials, Current Transplantation, Reports, 2016, 3(3), pp. 254-263.
[cited by applicant]
Shi, Y., et al., Inducing embryonic stem cells to differentiate to pancreatic β cells by a novel three-step approach with activin A and all-trans retinoic acid, Stem Cells, 2005, 23(5), pp. 656-662.
[cited by applicant]
Takahashi, K., et al., Inductions of pluripotent stem cells from mouse embryonic and adult fibroblast cultures and defined factors, Cell, 2006, 126(4), pp. 663-676.
[cited by applicant]
Takahashi, K., et al., Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 2007, 131(5), pp. 861-872.
[cited by applicant]
Tateishi, K., et al., Generation of insulin-secreting islet-like clusters from human skin fibroblasts, Journal of Biological Chemistry, 2008, 283(46), pp. 31601-31607.
[cited by applicant]
Tatum, J.A., et al., Single-donor islet transplantation in type 1 diabetes: patient selection and special consideration, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, 10, pp. 73-78.
[cited by applicant]
Tipanee, J., et al., Preclinical and clinical advances in transposon-based gene therapy, Bioscience Reports, 2017, 37(6), 20 pgs.
[cited by applicant]
Urnov, F.D., et al., Genome editing with engineered zinc finger nucleases, Nature Reviews Genetics, 2010, 11(9), pp. 636-646.
[cited by applicant]
Votey, M., et al., Of Mice and Men: How the NPOD Program is Changing the Way Researchers Study Type 1 Diabetes, DiaTribe, Aug. 21, 2015, 2 pgs., [online] diatribe.org/mice-and-men-how-npod-program-changing-way-researche…
[cited by applicant]
Walsh, N.C., et al., Humanized mouse models of clinical disease, Annual Review of Pathology: Mechanisms of Disease, 2017, 12, pp. 187-215.
[cited by applicant]
Wernig, M., et al., In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state, Nature, 2007, 448(7151), pp. 318-325.
[cited by applicant]
Yano, T., et al., Stromal cell-derived factor-1 (SDF-1/CXCL12) attenuates diabetes in mice and promotes pancreatic beta-cell survival by activation of the prosurvival kinase Akt., Diabetes, 2007, 56(12), pp. 2946-2957.
[cited by applicant]
Yu, J., et al., Induced pluripotent stem cell lines derived from human somatic cells, Science, 2007, 318, pp. 1917-1920.
[cited by applicant]
Zhang, Z., et al., CRISPR/Cas9 genome-editing system in human stem cells: current status and future prospects, Molecular Therapy-Nucleic Acids, 2017, 9, pp. 230-241.
[cited by applicant]
Brehm, M.A., et al., Advancing animal models of human type 1 diabetes by engraftment of functional human tissues in immunodeficient mice, Cold Spring Harbor Perspectives in Medicine, 2012, 2(5), a007757.
[cited by applicant]
Collier, J.J., et al., Pro-and antiapoptotic proteins apoptosis but do not protect against cytokine-mediated cytotoxicity in rat islets and B-cell lines, Diabetes, 2006, 55(5), pp. 1398-1406.
[cited by applicant]
Goping, I.S., et al., Cytotoxic T lymphocytes overcome Bcl-2 inhibition: target cells contribute to their own demise, Blood, 2008, 111(4), pp. 2142-2151.
[cited by applicant]
Luther, S.A., et al., Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocytes and dendritic cell recruitment and lymphoid neogenesis, The Journal of Immunology 2002, 169(1), pp. 424-433.
[cited by applicant]
Roep, B.O., et al., Animal models have little to teach us about Type 1 diabetes: 1. In support of this proposal, Diabetologia, 2004, 47(10), pp. 1650-1656.
[cited by applicant]
Van Craenenbroeck, K., et al., Episomal vectors for gene expression in mammalian cells, European Journal of Biochemistry, 2000, 267(18), pp. 5665-5678.
[cited by applicant]
Helman, A., et al., p16Ink4a-induced senescence of pancreatic beta cells enhances insulin secretion, Nature Medicine, 2016, 22(4), pp. 412-422.
[cited by applicant]
Sundararaman, S., et al., Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure, Gene Therapy, 2011, 18, pp. 867-873.
[cited by applicant]
Penn, M.S., et al., SDF-1 in myocardial repair, Gene Therapy, 2012, 19, pp. 583-587.
[cited by applicant]
Orimo, A., et al., Stromal Fibroblasts Presents in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion, Cell, 2005, 121, pp. 335-348.
[cited by applicant]
Ilhan, A., et al., CXCL12/SDF-1 over-expression in human insulinomas and its biological relevance, Molecular and Cellular Endocrinology, 2009, 298, pp. 1-10.
[cited by applicant]
GenBank E09668.1, cDNA encoding human SDF-1 alpha, 2005, 2 pgs.
[cited by applicant]
GenBank E09669.1, cDNA of human SDF-1 beta isoform, 2005 2 pgs.
[cited by applicant]
Leah, C., The Mouse Trap, Insulin Nation, Nov. 18, 2013 [online] https://insulinnation.com/treatment/cure-insight/the-mouse-trap/.
[cited by applicant]
Yang, H., et al., Human β Cells are Exceedingly Resistant to Streptozotocin In Vivo, Endocrinology, 2002, 143(7), pp. 2491-2495.
[cited by applicant]
Bhatt, J.M., et al., Expression of Epitope-Tagged Proteins in Mammalian Cells in Culture, Methods Mol. Biol., 2016, 1474: 3-24 (abstract).
[cited by applicant]
Cerignoli, F., et al., In vitro immunotherapy potency assays using real-time cell analysis, PLOS One, 2018, [online] https://doi.org/10.1371/journal.pone.0193498.
[cited by applicant]
Herberts, C., et al., Risk factors in the development of stem cell therapy, J. Transl. Med., 2011, 9, 29.
[cited by applicant]
Stewart, D., CRISPR-Cas9 DNA Editing Possibly Linked to Cancer, but CRISPR-Cas13d RNA Editing Could Offer New Avenues for Treatment, Dark Daily, Nov. 7, 2018, [online] https://www.darkdaily.com/crispr-cas9-dna-editing-p…
[cited by applicant]
Zhong, Y., et al., Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694, J. Biol. Chem. 2015, 290(10), pp. 5960-59780.
[cited by applicant]
Ansari, A., et al., Cellular GFP Toxicity and Immunogenicity: Potential Confounders in In Vivo Cell Tracking Experiments, Stem Cell Rev. 2016, 12(5), pp. 553-559.
[cited by applicant]
Kaja., S., et al., Quantification of Lactate Dehydrogenase for Cell Viability Testing Using Cell Lines and Primary Cultured Astrocytes, Current Protocols in Toxicology, 2017, Suppl. 72: 2.26.1-2.26.10.
[cited by applicant]
International Preliminary Report on Patentability for PCT App No. PCT/US2018/053599, mailed Apr. 16, 2020, 7 pgs.
[cited by applicant]